𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Selegiline as the primary treatment of Parkinson's disease — a long-term double-blind study

✍ Scribed by V. V. Myllylä; K. A. Sotaniemi; P. Hakulinen; O. Mäki-lkola; E. H. Heinonen

Book ID
109335616
Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
739 KB
Volume
95
Category
Article
ISSN
0001-6314

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Evaluation of acupuncture in the treatme
Evaluation of acupuncture in the treatment of Parkinson's disease: A double-blind pilot study
✍ Adrian Cristian; Meredith Katz; Eileen Cutrone; Ruth H. Walker 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB 👁 1 views

## Abstract As many as 40% of patients with Parkinson's disease (PD) use some form of complementary medicine during the course of their illness, and many try acupuncture. One nonblinded study of the effects of acupuncture in PD suggested that it might be helpful for some aspects of PD. We performed

A double-blind, placebo-controlled study
A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease
✍ Barry J. Snow; Fiona L. Rolfe; Michelle M. Lockhart; Christopher M. Frampton; Jo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 1 views

## Abstract Multiple lines of evidence point to mitochondrial oxidative stress as a potential pathogenic cause for Parkinson's disease (PD). MitoQ is a powerful mitochondrial antioxidant. It is absorbed orally and concentrates within mitochondria where it has been shown to protect against oxidative

Comparison of desipramine and citalopram
Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double-blind, randomized, placebo-controlled study
✍ David Devos; Kathy Dujardin; Isabelle Poirot; Caroline Moreau; Olivier Cottencin 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

## Abstract Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants

A double-blind, placebo-controlled study
A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease
✍ Richard B. Dewey Jr; Demetrius M. Maraganore; J. Eric Ahlskog; Joseph Y. Matsumo 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 677 KB

Nine patients with advanced levodopa-responsive Parkinson's disease were enrolled in a double-blind, placebo-controlled crossover trial of intranasal apomorphine as rescue therapy for parkinsonian off-states. Patients were assigned in random order to each of four possible combinations of apomorphine

Double-blind study of pardoprunox, a new
Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease
✍ Juliana Bronzova; Cristina Sampaio; Robert A. Hauser; Anthony E. Lang; Olivier R 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 1 views

## Abstract This study examined the efficacy and safety of the partial dopamine agonist, pardoprunox (SLV308), in the treatment of patients with early Parkinson's disease (PD). Patients were randomized to receive pardoprunox (n = 69) or placebo (n = 70). Pardoprunox was titrated to each patient's o